Literature DB >> 7724748

Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability--report of the Radiology Diagnostic Oncology Group.

A J Megibow1, X H Zhou, H Rotterdam, I R Francis, E A Zerhouni, D M Balfe, J C Weinreb, A Aisen, J Kuhlman, J P Heiken.   

Abstract

PURPOSE: To compare findings with computed tomography (CT) and magnetic resonance (MR) imaging in pancreatic adenocarcinoma and to determine optimal pulse sequences for MR imaging.
MATERIALS AND METHODS: CT scans and MR images were compared of 189 adult patients with known or suspected adenocarcinoma of the pancreas. Levels of confidence were correlated with surgical and pathologic results.
RESULTS: The accuracy of CT was 0.73 and of MR imaging was 0.70. The negative predictive value of CT was 0.28 and of MR imaging was 0.23. The positive predictive value of CT was 0.89 and of MR imaging was 0.88. Gradient-echo and T1-weighted spin-echo sequences ranked equally in evaluation of vascular invasion, T1-weighted spin-echo sequences were preferred for assessing lymphadenopathy, and T2-weighted spin-echo sequences were preferred for detecting hepatic metastases.
CONCLUSIONS: Cross-sectional imaging modalities are useful in the identification of unresectable pancreatic carcinoma. CT is recommended for initial imaging assessment.

Entities:  

Mesh:

Year:  1995        PMID: 7724748     DOI: 10.1148/radiology.195.2.7724748

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  38 in total

Review 1.  Management of upper gastrointestinal cancers.

Authors:  A Melville; E Morris; D Forman; A Eastwood
Journal:  Qual Health Care       Date:  2001-03

2.  An MRI-driven practice: a new perspective on MRI for the evaluation of adenocarcinoma of the head of the pancreas.

Authors:  Elliot B Tapper; Diego Martin; N Volkan Adsay; David Kooby; Bobby Kalb; Juan M Sarmiento
Journal:  J Gastrointest Surg       Date:  2010-05-14       Impact factor: 3.452

3.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.

Authors: 
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 4.  Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.

Authors:  Domenico Tamburrino; Deniece Riviere; Mohammad Yaghoobi; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2016-09-15

Review 5.  Endoscopic ultrasonography in the diagnosis and staging of pancreatic neoplasms.

Authors:  P Protiva; A V Sahai; B Agarwal
Journal:  Int J Gastrointest Cancer       Date:  2001

Review 6.  Pancreatic neoplasia: a practical cross-sectional imaging primer for the nonradiologist.

Authors:  Matthew T Heller; Nathan Johnson; Antonio Fargiano
Journal:  J Gastrointest Cancer       Date:  2012-06

7.  Magnetic resonance angiography in the resectability assessment of suspected pancreatic tumours.

Authors:  O Smedby; V Riesenfeld; B Karlson; G Jacobson; A Löfberg; P G Lindgren; H Ahlström
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

8.  High-resolution MRI of pancreatic masses with a new circularly polarized body phased-array coil.

Authors:  K Engelhard; H P Hollenbach
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

9.  Assessment of vascular invasion in pancreatic head cancer with multislice spiral CT: value of multiplanar reconstructions.

Authors:  Melanie Brügel; Thomas M Link; Ernst J Rummeny; Peter Lange; Jörg Theisen; Martin Dobritz
Journal:  Eur Radiol       Date:  2004-04-09       Impact factor: 5.315

10.  Does Second Reader Opinion Affect Patient Management in Pancreatic Ductal Adenocarcinoma?

Authors:  Giuseppe Corrias; Sandra Huicochea Castellanos; Ryan Merkow; Russel Langan; Vinod Balachandran; Monica Ragucci; Gabriella Carollo; Marcello Mancini; Luca Saba; Lorenzo Mannelli
Journal:  Acad Radiol       Date:  2018-01-17       Impact factor: 3.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.